Cite
HARVARD Citation
Naumann, U. et al. (2019). Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2%. International journal of STD & AIDS. pp. 727-728. [Online].